Transgene Biotek Reports Q3 FY26 Loss of ₹37.38 Lakhs

Transgene Biotek Limited posted a net loss of ₹37.38 lakhs for Q3 FY26 ended December 31, 2025, compared to ₹8.90 lakhs loss in Q3 FY25. Revenue declined to ₹5.45 lakhs from ₹7.65 lakhs year-on-year.

Transgene Biotech faces SEBI recovery proceedings

Transgene Biotech Limited receives SEBI prohibitory order for Rs.38 lacs penalty non-payment, resulting in asset freeze and operational paralysis while appeal remains pending at Securities Appellate Tribunal.

Transgene Biotek Reports Net Loss and Board Approvals for AGM and Director Reappointments

Transgene Biotek Limited's board approved quarterly results showing a net loss of Rs. 38.84 lakhs for September 2025 quarter and scheduled its 35th AGM for December 30, 2025. The company reappointed Dr. K. Koteswara Rao as Chairman Managing Director for one year and three independent directors for five-year terms, while facing ongoing legal challenges at SAT Mumbai and Appellate Tribunal New Delhi.

Transgene Biotek Faces Legal Case Over Rs 6.82 Crore Unpaid Loan at NCLT

Transgene Biotek Ltd received notification that Babaji Nethralayya Pvt Ltd has filed a legal case at the NCLT Hyderabad bench over an unpaid loan amount of Rs 6,82,05,834 along with interest and other charges. The matter was heard on October 16, 2025, and has been adjourned to December 16, 2025. The company stated it is making efforts to resolve the matter amicably.

Transgene Biotek Reports Loss of Rs 43.37 Lakhs in Q1, Appoints New Auditors

Transgene Biotek Limited's Board approved quarterly financial results showing a net loss of Rs 43.37 lakhs for the quarter ended June 30, 2025, compared to a profit of Rs 19.94 lakhs in the same period last year. Revenue from operations declined to Rs 4.95 lakhs from Rs 4.92 lakhs year-over-year. The company's total expenses increased to Rs 48.32 lakhs, with finance costs rising significantly to Rs 24.55 lakhs from Rs 1.73 lakhs in the previous year. The Board extended the AGM date for financial year 2024-25 and appointed M/s. Manisha Dubey & Associates as Internal Auditors for 2025-26, and M/s. Geeta Serwani & Associates as Secretarial Auditors for a five-year term from April 2025 to March 2030, subject to shareholder approval. The company continues to face challenges due to ongoing SEBI adjudication proceedings, with the next SAT hearing scheduled for September 8, 2025.